





**Cell Reports, Volume 29**

**Supplemental Information**

**A tRNA-Derived Small RNA Regulates  
Ribosomal Protein S28 Protein Levels  
after Translation Initiation in Humans and Mice**

**Hak Kyun Kim, Jianpeng Xu, Kirk Chu, Hyesuk Park, Hagoon Jang, Pan Li, Paul N. Valdmanis, Qiangfeng Cliff Zhang, and Mark A. Kay**




**I**

target-A in CDS mfe: -23.7 kcal/mol







target 5' A	176	A	193	3'
	GGUG C	GAGUGG AUUC		
	CCAC G	CUCACC UAAG		
tsRNA 3' A	A UC	C CU	5'	

target-B in 3'UTR m.f.e.: -24.6 kcal/mol


target 5' U	303	CU	321	3'
	UG CAG	GGUGGGUUC		
	AC GUC	UCACCCUAAG		
tsRNA 3' ACC	A C	CU	5'	




**Figure S1. Related to Figure 1 – LeuCAG3'tsRNA and its target site in CDS of *RPS28* mRNA is conserved between vertebrate species.** (A) Proposed model of LeuCAG3'tsRNA-mediated translation regulation in human cells (Kim et al., 2017). The LeuCAG3'tsRNA is processed from the mature Leu-CAG tRNA by an unknown process. It binds to two target sites (red colored region) in human *RPS28* mRNA and unwinds the secondary structure of the target sites during translation, maintaining a specific concentration of RPS28 protein and 40S ribosomes. (B) The detailed human *RPS28* mRNA (NM\_001031.4) secondary structure is depicted. Grey, untranslated region (UTR); Black, coding sequences (CDS); Blue, the potential binding sites of the LeuCAG3'tsRNA. Translation initiation site (TIS) is indicated as black-bold characters. (C) The percent identity across 13 vertebrate species is depicted. Each percent identity is 95 or 100 demonstrating that LeuCAG3'tsRNA sequence is either identical or different by 1 nt between diverse vertebrate species. (D) The sequence alignments of target-A (left) and target-B sites (right) in *RPS28* mRNA for LeuCAG3'tsRNA across different species. The targets of LeuCAG3'tsRNA in *RPS28* mRNA of each species were predicted using RNAhybrid. *M. musculus* (T1) and (T2) are mouse *Rps28* transcript 1 and transcript 2, respectively. Black-colored nucleotides are the predicted target sites in each species. \*, conserved site. (E) The average phyloP conservation score (y-axis) of each 22-nucleotide-long sliding window (x-axis) through the *RPS28* CDS across 100 vertebrate species. The red-colored consecutive seven, 22-nucleotide windows span the entire LeuCAG3'tsRNA target site. The average conservation score of a group of these seven windows is 5.75, which is the second highest score among those of all grouped consecutive seven, 22-nucleotide windows that span the whole *RPS28* CDS. (F, G, H) Schematic of the *RPS28* mRNA secondary structure predicted by RNAfold. *P.troglodytes* *RPS28* (XM\_003953343.3) (F). *M.mulatta* *RPS28* (NM\_001193436.1) (G). *C.lupus* *RPS28* (XM\_542128.5) (H). Grey, untranslated region (UTR); Black, coding sequences (CDS); Blue, the potential binding sites of the LeuCAG3'tsRNA. Translation initiation site (TIS) is indicated as black-bold characters. (I) The thermodynamic potential of LeuCAG3'tsRNA binding sites in the mouse *Rps28* mRNA: the target-A (nt 176 to 193) in the CDS and the target-B (nt 303 to 321) in the 3' UTR. The binding site is predicted by RNAhybrid. Indicated numbers on each diagram represents the 5' end and 3' end position of the target site of the mouse *Rps28* mRNA, respectively. (J) Schematic of the mouse *Rps28* mRNA (NM\_001355384.1) secondary structure predicted by RNAfold. Blue, the possible binding sites of the LeuCAG3'tsRNA. Red, the altered nucleotides of the non-target *RPS28* mutant.

**A****B****C****D****E****F**

**Figure S2. Related to Figure 2 – Antisense oligonucleotides targeting the LeuCAG3'tsRNA specifically inhibits the LeuCAG3'tsRNA and mouse RPS28 is required for ribosomal RNA processing in a mouse hepatoma cell line.** (A) Total RNA was extracted from both cells and subjected to northern hybridization. The markers are synthesized oligonucleotides containing LeuCAG3'tsRNA sequences. U6 small nuclear RNA and LeuCAG tRNA are loading controls (n=2 independent experiments). (B) Northern analysis of the LeuCAG3'tsRNA and mature Leu-CAG tRNA post-transfection. The tsRNA (22 nt) and mature tRNA (around 100 nt) were detected with the same probe. To quantify and compare the relative amount of the mature tRNA, the blot was exposed for a shorter time after detecting the tsRNA (n=2 independent experiments). U6 snRNA and mature LeuCAG tRNA are the loading controls. (C) Schematic picture showing putative binding sites and binding structure of the anti-Leu3'ts ASO on the 45S primary transcript (45S pre-rRNA). To identify the tsRNA binding sites in the 45S pre-rRNA, we used the RNAhybrid program and 22-nt sequence from the 3' end of LeuCAG-tRNA. The resulting two putative binding sites were positioned in the 5'ETS, two sites in 18S rRNA, one site in ITS1, one site in ITS2, and four sites in 28S rRNA, all of which have more than two mis-matches or a bulge except for the one binding site in 28S rRNA. The putative anti-Leu3'ts oligonucleotide binding site is indicated as a bar. (D) The potential interaction of Anti-LeuCAG3'tsRNA oligonucleotide and mouse *Rps28* mRNA: All of the potential interactions have more than two mis-matches. All binding sites were predicted by RNAhybrid. Indicated numbers on each diagram represents the 5' end and 3' end position of the target site on mouse 45S pre-rRNA or *Rps28* mRNA, respectively. (E, F) Knockdown of the *Rps28* mRNA accumulated 34S pre-rRNA in Hepa 1-6 cells. Northern hybridization was performed with total RNA from Hepa 1-6 cells 24 h post-transfection (n=2 independent experiments). The ITS1 probe detects the 45S primary transcript and intermediate forms of the mature 18S rRNA including 34S, 29S, and 18S-E pre-rRNAs. The 47S and 29S pre-rRNAs are normally short-lived in cells due to their rapid processing. Mouse ribosomal RNA processing is depicted in Figure 2B (E). The RPS28 protein level was measured by western blot 24 h post-transfection (n=2 independent experiments) (F).



**Figure S3. Related to Figure 3 – Inhibition of LeuCAG3'tsRNA reduced the number of ribosomes associated with *Rps28* mRNA, while *Nop10* and *Gapdh* mRNA were unaffected.** Polysome analysis was performed using sucrose gradient fractionation 24 h post-transfection and subsequently northern hybridization was performed with the extracted RNA from each fraction (for *RPS28*, n=5 independent experiments; for *Nop10* and *GAPDH*, n=3 independent experiments). **(A)** Polysome profiles indicates the position of the 40S and 60S ribosomal free subunit, 80S monosome, and polysomes for each fraction. **(B)** Each fraction value for the specific mRNA was normalized to the sum of the mRNA level across all gradient fractions. **(C)** A represented northern image. X-axis, fraction number. con, control; Anti, Anti-LeuCAG3'tsRNA. The mean is indicated. Error bar, s.d. \*, P<0.05 by two-tailed t-test.



**Figure S4. Related to Figure 4 – LeuCAG3' tsRNA regulates RPS28 post-translational initiation in both HeLa and Hepa 1-6 cells.** The polysome profile (top) and northern hybridization (bottom) in each panel were analyzed 24 h post-transfection. The polysome profile indicates the position of ribosomal free subunit, monosome, and polysomes for each designated fraction and shows that the treatment with sodium arsenite (solid line) inhibits the formation of polysomes. **(A)** In HeLa cells, depletion of RPL7 and RPL35A, components of the 60S ribosome stalls RPS28 and RPS23 mRNA migration to fractions near the 40S subunit (n=2 independent experiments). Western blot showing depleted RPL7 and RPL35A protein levels by siRNA knockdown in the right panel. GAPDH is a loading control. **(B)** Sodium arsenite treatment stalls RPS28 and GAPDH mRNA at the 80S monosome in HeLa cells (n=2 independent experiments). **(C)** Sodium arsenite treatment stalls RPS28 and GAPDH mRNA at the 80S monosome regardless of the inhibition of LeuCAG3' tsRNA in HeLa (left) and Hepa 1-6 (right) cells (n=2 independent experiments). SA (+), treatment of sodium arsenite; SA (-), no treatment of sodium arsenite; con, control; Anti, Anti-LeuCAG3' tsRNA. **(D)** LeuCAG3' tsRNA co-migrates with polysomal fractions. Cytoplasmic lysates from HeLa cells were treated with cycloheximide or puromycin and separated by ultracentrifugation in 10–50% sucrose gradients. Total RNAs were extracted from each fraction, separated on a denaturing 15% acrylamide gel, and subjected to northern hybridization (n=2 independent experiments). Upper graph is the ribosomal profile detected at 254nm UV showing sucrose gradient fractionation discriminates the 40S and 60S ribosomal free subunits, 80S monosome, and polysomes. The percentage below the LeuCAG3' tsRNA northern result indicates the relative LeuCAG3' tsRNA abundance in fractions normalized to the sum of the LeuCAG3' tsRNA level across all gradient fractions.

sample	Transcript 1 (short form)	Transcript 2 (long form)	others	GEO accession number
liver control rep1		44	3	<a href="#">GSM1694991</a>
liver control rep2		89		<a href="#">GSM1694992</a>
liver_U6-sh- hAAT 25nt rep1		52	2	<a href="#">GSM1694993</a>
liver_U6-sh- hAAT 25nt rep2		58		<a href="#">GSM1694994</a>
liver_H1-sh- hAAT 25nt rep1	1	43		<a href="#">GSM1694995</a>
liver_H1-sh- hAAT 25nt rep2		43		<a href="#">GSM1694996</a>

**Table S1. Related to Figure 1 – Relative expression of mouse *Rps28* transcript variants in whole liver.** The number in each transcript column indicates the number of reads that span the splice junction (overlapping both exons).



NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
1.000	1.000	0.000	0.381	0.033	0.120	0.296	0.556	0.315	0.381	0.330
0.365	0.058	0.108	0.333	0.377	0.061	0.061	0.118	0.029	0.073	0.141
0.040	0.151	0.344	0.000	0.186	0.199	0.063	0.042	0.233	0.118	0.110
0.056	0.022	0.096	0.087	0.197	0.059	0.048	0.022	0.030	0.008	0.012
0.010	0.007	0.049	0.004	0.000	0.000	0.000	0.058	0.014	0.000	0.057
0.076	0.052	0.042	0.017	0.034	0.039	0.004	0.134	0.112	0.068	0.122
0.306	0.381	0.483	0.104	0.000	0.035	0.201	0.192	0.199	0.259	0.131
0.058	0.042	0.032	0.023	0.059	0.051	0.046	0.084	0.128	0.423	0.162
0.004	0.003	0.169	0.148	0.371	0.069	0.129	0.130	0.192	0.151	0.057
0.045	0.283	0.152	0.133	0.231	0.292	0.232	0.070	0.035	0.002	0.035
0.152	0.327	0.213	0.420	0.122	0.245	0.127	0.106	0.171	0.124	0.063
0.020	0.029	0.009	0.120	0.118	0.175	0.038	0.000	0.128	0.103	0.075
0.089	0.090	0.019	0.330	0.233	0.119	0.114	0.006	0.031	0.071	0.091
0.000	0.025	0.050	0.019	0.000	0.134	0.305	0.762	0.120	0.301	0.384
0.247	0.040	0.230	0.423	0.695	1.000	0.430	0.404	0.980	0.269	0.497
0.711	0.580	0.240	0.262	0.132	0.066	0.000	0.000	0.103	0.504	0.452
0.124	0.028	0.181	0.097	0.206	0.020	0.018	0.012	0.017	0.007	0.028
0.000	0.024	0.300	0.164	0.022	0.458	0.000	0.000	0.000	0.000	0.000
0.000	0.156	0.523	0.281	0.151	0.151	0.222	0.365	0.678	0.267	0.152
0.409	0.622	1.000	0.786	0.478	0.630	0.393	0.910	0.794	0.569	0.462
0.350	0.142	0.128	0.651	0.646	0.249	0.399	0.402	0.418	0.585	0.224
0.296	0.724	0.739	0.845	1.000	1.000	0.393	0.468	0.471	0.368	0.052
0.000	0.020	0.019	0.000	0.031	0.113	0.001	0.013	0.004	0.001	0.040
0.021	0.040	0.015	0.011	0.013	0.023	0.052	0.098	0.246	0.870	0.171
0.000	0.000	0.039	0.003	0.040	0.071	0.056	0.086	0.123	0.113	0.023
0.000	0.000	0.000	0.022	0.004	0.017	0.028	0.084	0.027	0.022	0.013
0.015	0.009	0.000	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL

**Table S2. Related to Figure 1 – icSHAPE scores for the full-length mouse *Rps28* transcript 2 (ENSMUST00000173844.7).** Each number represents the scores for each nucleotide.

Human <i>GAPDH</i> mRNA: 5'-agatcatcagcaatgcctcct-3' and 5'-tggtcatgagtcctccacg-3'	IDT	N/A
Human <i>RPS28</i> mRNA: 5'-gccgcatggacaccagccgtgtgc-3' and 5'-tcagcgaacctccgggcttc-3'	IDT	N/A
Human <i>RPS23</i> mRNA: 5'-gccgcatgggcaagtgtcgtggac-3' and 5'-ttatgatcttggctttccttc-3'	IDT	N/A
Mouse <i>Gapdh</i> mRNA: 5'-acccttcattgacctcaacta-3' and 5'-cttctcatgggtggaagac -3'	IDT	N/A
Mouse <i>Rps28</i> : 5'-ctcgcgagagcgaagtgag-3' and 5'-taatataaatgctttattaacagttgcag-3'	IDT	N/A

**Table S3. Related to STAR Methods – PCR primers used as northern probes for mRNAs.**

Mouse <i>Rps28</i> target-A mutant: 5'- gagcggctgggtcatccataaactcgaccctgacttgctgcaactgtccctgcca-3' and 5'- tcgcaggacagtgacgcaagtcagggtcgagttatggatgacaccagccgctc-3'	IDT	N/A
Mouse <i>Rps28</i> target-B mutant: 5'-agagaagctcgaaggtgcgtaactctggatatccactac-3' and 5'- gtagtggatatccaagattaacgcaacctcgagcttctc-3'	IDT	N/A
Mouse <i>Rps28</i> non-target mutant: 5'- ttcgacttctctttctgactgcagcaatgtcaggacgtcacctctcgaacggggcc-3' and 5'- ggccccgttcgagagggtgacgtcctgacattgctgcagtcagaagagaagctcga-3'	IDT	N/A

**Table S4. Related to STAR Methods – Oligonucleotides used for site-directed mutagenesis.**